Loading events...
Oral presentation at ASH 2025 to feature pivotal Phase 3 results of Xervyteg® (MaaT013), including previously disclosed primary endpoint data (62% GI-ORR at Day 28) and new findings on secondary endpoints (data at Day 56 and 3 months, and duration of response). Results highlight strong efficacy and indicate a favorable safety profile for Xervyteg® (MaaT013), reinforcing its potential to become the first third-line treatment for patients with gastrointestinal aGvHD unresponsive to current therapi
Saturday, December 6, 2025 - Tuesday, December 9, 2025
Geneva, USA
Oral presentation at ASH 2025 to feature pivotal Phase 3 results of Xervyteg® (MaaT013), including previously disclosed primary endpoint data (62% GI-ORR at Day 28) and new findings on secondary endpoints (data at Day 56 and 3 months, and duration of response). Results highlight strong efficacy and indicate a favorable safety profile for Xervyteg® (MaaT013), reinforcing its potential to become the first third-line treatment for patients with gastrointestinal aGvHD unresponsive to current therapi
Receive curated event recommendations based on your interests.
See how WebMobi helps you manage registration, check-in, and analytics.
Request a DemoOr start free →ASH Congress 2025 takes place on Saturday, December 6, 2025 to Tuesday, December 9, 2025 in Geneva. All times are in UTC.
WebMobi provides event registration, ticketing, mobile apps, check-in, and analytics — all with zero platform fees.
Get curated B2B events, AI-powered insights, and industry trends delivered to your inbox